In a significant development for India’s pharmaceutical sector, small and medium enterprises (MSMEs) are poised for a major makeover under the revamped Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS). Dr. Arunish Chawla, Secretary of the Department of Pharmaceuticals (DoP), revealed that numerous companies are stepping up following comprehensive gap analyses.
Dr. Chawla shared these insights during the 9th Global Pharmaceutical Quality Summit (GPQS) in Mumbai, which concluded on June 28, 2024. Hosted by the Indian Pharmaceutical Alliance (IP Alliance), the summit gathered industry leaders, global regulators, quality experts, and stakeholders under the theme “Advances in Manufacturing and Quality – Patient Centricity.”
The revitalized PTUAS aims to bolster MSMEs by facilitating upgrades in technology and infrastructure to meet international benchmarks. Financial assistance under the scheme will aid MSMEs in enhancing manufacturing facilities, adopting good manufacturing practices, and boosting overall competitiveness. By addressing existing gaps, the initiative empowers these enterprises to produce high-caliber pharmaceuticals and expand their market presence.
Dr. Chawla also announced the imminent approval of the first batch of applications under the revised PTUAS scheme, marking a pivotal phase for India’s Pharma MSMEs. Looking ahead, he emphasized a forthcoming wave of transformation as more MSMEs engage post-gap analysis.
Moreover, Dr. Chawla unveiled the IPA Best Practices Guideline on Good Engineering Practices and Process Analytical Tools during the summit. Stressing on quality in the pharmaceutical sector, he underscored its critical role in market reputation, patient safety, and community welfare. Dr. Chawla noted India’s strides towards surpassing WHO GMP standards in specific domains, aligning with the national vision of ‘Zero defect and Zero effect.’
Highlighting the imperative of investment in quality and adherence to rigorous standards, Dr. Chawla reiterated India’s commitment to producing world-class pharmaceuticals. Audits slated to commence in July 2024 aim to further fortify India’s pharmaceutical industry stature on the global stage.